Ocugen, Inc. (OCGN)
1.34
-0.05
(-3.60%)
USD |
NASDAQ |
May 18, 16:00
1.345
0.00 (0.00%)
After-Hours: 20:00
Ocugen Research and Development Expense (Quarterly) : 11.26M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 53.48M |
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| Sarepta Therapeutics, Inc. | 153.96M |
| Krystal Biotech, Inc. | 13.81M |
| Gilead Sciences, Inc. | 1.354B |